Obesity Management Market Forecast 2022 to 2032 | By Drug Type, Surgery Type, Distribution Channel & Region

The global Obesity Management Market size is expected to be valued at US$ 1,362.80 million in 2032, with the market developing at a moderate CAGR of 5.1% from 2022 to 2032. The Obesity Management market, predicted to be worth US$ 828.71 million in 2022, is being driven by the significant rise in obesity and obesity-related health concerns. Obesity pollution has increased, resulting in a rising demand for Obesity Management programmes. Over the projection term, this bodes well for the Obesity Management industry.

With an increase in the number of bariatric surgeries, as well as an increase in the adoption of online weight loss and weight management programmes, growth in disposable income in emerging economies, sedentary lifestyle, and favourable government initiatives, obesity awareness has increased. Along with this increased awareness, there has been a significant growth in the demand for Obesity Management.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-587

The Obesity Management market has grown significantly in most industrialised countries with an expanding geriatric population, owing to improved healthcare services and, as a result, greater life expectancy. Because the senior population is prone to developing visible body fat while losing muscle mass and functioning abilities, this age group is a big market driver in both the short and long term. Furthermore, genetics and drug side effects that cause obesity contribute to market expansion.

In spite of facing positive future market prospects, the target market is not without its share of challenges. High costs of surgeries and drugs coupled with safety issues may hinder the progress of the Obesity Management market in the global space over the forecast period.

“Prevailing sedentary lifestyle results in a surge in obese population which, in turn, is expected to propel the market growth of Obesity Management over the forecast period,” says an FMI analyst.  

Key Takeaways:

• Rising adoption of weight loss and weight management programs to drive market growth.
• Concerns about the safety of Obesity Management drugs may hamper the market growth.
• Liraglutide registered the largest market share of 32.4%.
• By surgery type, gastric sleeve surgery is expected to dominate the market.
• The US is expected to maintain a high growth rate over the forecast period.
• The Obesity Management market in Europe to contribute significantly to the global revenue.

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-587

Competitive Landscape 

GlaxoSmithKline Plc, VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. and others, are some of the major players in the Obesity Management market that are profiled in the full version of the report.

In a consolidated market, major players are increasing investment in research and development activities for product innovation, development and upgradation of existing products.

More Insights into the Obesity Management Market Report

In its latest report, FMI offers an unbiased analysis of the global Obesity Management market, providing historical data and forecast statistics for 2022 to 2032. To understand the global market potential, growth, and range, the market is segmented on the basis of drug type (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), surgery type (Gastric Bypass Surgery, Adjustable Gastric Banding Surgery, Gastric Sleeve Surgery, Duodenal Switch Surgery, Others), distribution channels (hospital pharmacies, retail pharmacies, e-commerce), and region.

According to the latest FMI reports, based on region, the Obesity Management market in North America is predicted to undergo remarkable growth over the assessment period. The regional market is primarily driven the target market’s growth in the US The US, is expected to maintain a high growth rate over the assessment period. Growing incidences of obesity and associated diseases coupled with the presence of major market players will drive the market growth in North America.

Apart from North America, Europe and the Asia Pacific are also anticipated considerable growth of the market. Heightened consumption of processed meat is increasing obesity cases in Europe which results in a healthy target market. Asia Pacific is emerging as a lucrative market opportunity for Obesity Management programs.

Visit For Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-587

Key Segments

By Drug Type:

• Bupropion and Naltrexone
• Orlistat
• Lorcaserin
• Phentermine and Topiramate
• Liraglutide

By Surgery Type:

• Gastric Bypass Surgery
• Adjustable Gastric Banding Surgery
• Gastric Sleeve Surgery
• Duodenal Switch Surgery
• Others

By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• E-commerce

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs